TrialPLoS pathogens2017

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

David Easterhoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.